With regard to PCa, the prostatic-specific membrane antigen (PSMA), discovered by Heroszewicz et al. in 1987 [10,12], continues to increase in importance as a molecular target for the development of target-specific agents for (radio)pharmaceutical applications [10]. Here, FOLH1 is linked to posterior cortical atrophy.